Adrenocortical carcinoma - Surgical progress or status quo?

被引:108
作者
Kendrick, ML
Lloyd, R
Erickson, L
Farley, DR
Grant, CS
Thompson, GB
Rowland, C
Young, WF
van Heerden, JA
机构
[1] Mayo Clin, Dept Surg, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Pathol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Endocrinol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Stat, Rochester, MN 55905 USA
关键词
D O I
10.1001/archsurg.136.5.543
中图分类号
R61 [外科手术学];
学科分类号
摘要
Hypothesis: Outcome of patients with adrenocortical carcinoma (ACC) has improved with the advent of more widely available and higher quality imaging. Operative management strategies and use of adjuvant therapy have not changed. Design: Retrospective review of patient histories, imaging studies, operative data, adjuvant therapy, and outcomes at a single institution. Follow-up was complete for a mean of 53 months. Data was compared with prior institutional experience. Setting: Tertiary care referral center. Patients: All patients undergoing operative management for ACC during the period from 1980 to 1996. Main Outcome Measures: Determinants of recurrence, survival, and the effect of adjuvant therapy on overall outcome. Results: Fifty-eight patients (30 men, 28 women) with a mean age of 53 years underwent primary operative e management for ACC. Functional tumors were identified in 27 patients (47%). Mean tumor size was 12.5 cm. Stage according to the TNM staging system (AJCC Cancer Staging Manual) at presentation was I (n=0), II (n=30), III (n=7), and IV (n=21). Surgical management included curative resection in 41 (71%), noncurative resection in 14 (24%), and open biopsy in 3 (5%). Perioperative mortality was 5%. Recurrence occurred in 30 patients (73%) with a median time to recurrence of 17 months. Five year survival by the Kaplan-Meier method was 37%. Prognostic factors (P<.05) included functional status, stage, and chemotherapy in stage III/IV patients. When compared with our prior institutional experience (1960-1980), current patients were more likely to present with stages 1 to 11 (52% vs 34%), have curative resections (71% vs 50%), and have improved 5-year survival (37% vs 16%). Conclusions: (1) Surgical resection remains the principal treatment for stage I to III disease. (2) Adjuvant therapy may improve survival in patients with stage III or IV disease. (3) Current patients were more likely to present at an earlier stage, undergo curative resections, and have improved 5-year survival than institutional historical comparisons.
引用
收藏
页码:543 / 548
页数:6
相关论文
共 25 条
[1]   Can adrenal incidentalomas be safely observed? [J].
Barry, MK ;
van Heerden, JA ;
Farley, DR ;
Grant, CS ;
Thompson, GB ;
Ilstrup, DM .
WORLD JOURNAL OF SURGERY, 1998, 22 (06) :599-604
[2]   ADRENOCORTICAL CARCINOMA [J].
BRENNAN, MF .
CA-A CANCER JOURNAL FOR CLINICIANS, 1987, 37 (06) :348-365
[3]   Is there a role for low doses of mitotane (o,p′-DDD) as adjuvant therapy in adrenocortical carcinoma? [J].
Dickstein, G ;
Shechner, C ;
Arad, E ;
Best, LA ;
Nativ, O .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (09) :3100-3103
[4]   ADRENAL INCIDENTALOMA [J].
GAJRAJ, H ;
YOUNG, AE .
BRITISH JOURNAL OF SURGERY, 1993, 80 (04) :422-426
[5]   OPTIMAL TREATMENT OF ADRENOCORTICAL CARCINOMA WITH MITOTANE - RESULTS IN A CONSECUTIVE SERIES OF 96 PATIENTS [J].
HAAK, HR ;
HERMANS, J ;
VANDEVELDE, CJH ;
LENTJES, EGWM ;
GOSLINGS, BM ;
FLEUREN, GJ ;
KRANS, HMJ .
BRITISH JOURNAL OF CANCER, 1994, 69 (05) :947-951
[6]  
Heniford BT, 1999, SEMIN SURG ONCOL, V16, P293, DOI 10.1002/(SICI)1098-2388(199906)16:4<293::AID-SSU4>3.0.CO
[7]  
2-E
[8]  
HENLEY DJ, 1983, SURGERY, V4, P926
[9]   CLINICAL-FEATURES OF ADRENOCORTICAL CARCINOMA, PROGNOSTIC FACTORS, AND THE EFFECT OF MITOTANE THERAPY [J].
LUTON, JP ;
CERDAS, S ;
BILLAUD, L ;
THOMAS, G ;
GUILHAUME, B ;
BERTAGNA, X ;
LAUDAT, MH ;
LOUVEL, A ;
CHAPUIS, Y ;
BLONDEAU, P ;
BONNIN, A ;
BRICAIRE, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (17) :1195-1201
[10]  
MACFARLANE D A, 1958, Ann R Coll Surg Engl, V23, P155